Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma
Nizar M. Tannir, Lorenzo Cohen, Xuemei Wang, Peter Thall, Paul F. Mathew, Eric Jonasch, Arlene Siefker-Radtke, Lance C. Pagliaro, Chaan S. Ng, Christopher LogothetisVolume:
107
Année:
2006
Langue:
english
Pages:
8
DOI:
10.1002/cncr.22253
Fichier:
PDF, 132 KB
english, 2006